Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus.
Following the initial observation by Dr. Margaret Fischl that trimethoprim-sulfamethoxazole can prevent Pneumocystis carinii infection in patients with Kaposi's sarcoma, initiating prophylaxis for pneumocystic infection in all patients with less than 200 CD4+ cells/mm3 has become accepted practice. This prophylactic intervention has been found not only to reduce the development of pneumonia due to P. carinii but also to prolong life. Drs. Henry Masur and Joseph A. Kovacs first reviewed prophylaxis for P. carinii pneumonia in patients infected with the human immunodeficiency virus for the AIDS Commentary 3 years ago. They have updated that initial review for this AIDS Commentary, placing currently available information into concise clinical perspective and detailing a rational plan for the clinician to follow based on results of recent studies.
Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland 20892.
J A
JA
Kovacs
H
H
Masur
D000280:Administration, Inhalation; D000336:Aerosols; D015496:CD4-Positive T-Lymphocytes; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007958:Leukocyte Count; D009894:Opportunistic Infections / Q000517:prevention & control*; D010419:Pentamidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D012307:Risk Factors; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use
D000336:Aerosols; D015215:Zidovudine; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination